Unsupervised mobile cognitive testing for use in preclinical Alzheimer's disease
Abstract Introduction Unsupervised digital cognitive testing is an appealing means to capture subtle cognitive decline in preclinical Alzheimer's disease (AD). Here, we describe development, feasibility, and validity of the Boston Remote Assessment for Neurocognitive Health (BRANCH) against in‐...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/dad2.12243 |
| _version_ | 1828085264172449792 |
|---|---|
| author | Kathryn V. Papp Aubryn Samaroo Hsiang‐Chin Chou Rachel Buckley Olivia R. Schneider Stephanie Hsieh Daniel Soberanes Yakeel Quiroz Michael Properzi Aaron Schultz Iván García‐Magariño Gad A. Marshall Jane G. Burke Raya Kumar Noah Snyder Keith Johnson Dorene M. Rentz Reisa A. Sperling Rebecca E. Amariglio |
| author_facet | Kathryn V. Papp Aubryn Samaroo Hsiang‐Chin Chou Rachel Buckley Olivia R. Schneider Stephanie Hsieh Daniel Soberanes Yakeel Quiroz Michael Properzi Aaron Schultz Iván García‐Magariño Gad A. Marshall Jane G. Burke Raya Kumar Noah Snyder Keith Johnson Dorene M. Rentz Reisa A. Sperling Rebecca E. Amariglio |
| author_sort | Kathryn V. Papp |
| collection | DOAJ |
| description | Abstract Introduction Unsupervised digital cognitive testing is an appealing means to capture subtle cognitive decline in preclinical Alzheimer's disease (AD). Here, we describe development, feasibility, and validity of the Boston Remote Assessment for Neurocognitive Health (BRANCH) against in‐person cognitive testing and amyloid/tau burden. Methods BRANCH is web‐based, self‐guided, and assesses memory processes vulnerable in AD. Clinically normal participants (n = 234; aged 50–89) completed BRANCH; a subset underwent in‐person cognitive testing and positron emission tomography imaging. Mean accuracy across BRANCH tests (Categories, Face‐Name‐Occupation, Groceries, Signs) was calculated. Results BRANCH was feasible to complete on participants’ own devices (primarily smartphones). Technical difficulties and invalid/unusable data were infrequent. BRANCH psychometric properties were sound, including good retest reliability. BRANCH was correlated with in‐person cognitive testing (r = 0.617, P < .001). Lower BRANCH score was associated with greater amyloid (r = –0.205, P = .007) and entorhinal tau (r = –0.178, P = .026). Discussion BRANCH reliably captures meaningful cognitive information remotely, suggesting promise as a digital cognitive marker sensitive early in the AD trajectory. |
| first_indexed | 2024-04-11T04:36:58Z |
| format | Article |
| id | doaj.art-801c51ff438d4660bd858faddcdffe38 |
| institution | Directory Open Access Journal |
| issn | 2352-8729 |
| language | English |
| last_indexed | 2024-04-11T04:36:58Z |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring |
| spelling | doaj.art-801c51ff438d4660bd858faddcdffe382022-12-28T09:12:14ZengWileyAlzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring2352-87292021-01-01131n/an/a10.1002/dad2.12243Unsupervised mobile cognitive testing for use in preclinical Alzheimer's diseaseKathryn V. Papp0Aubryn Samaroo1Hsiang‐Chin Chou2Rachel Buckley3Olivia R. Schneider4Stephanie Hsieh5Daniel Soberanes6Yakeel Quiroz7Michael Properzi8Aaron Schultz9Iván García‐Magariño10Gad A. Marshall11Jane G. Burke12Raya Kumar13Noah Snyder14Keith Johnson15Dorene M. Rentz16Reisa A. Sperling17Rebecca E. Amariglio18Center for Alzheimer Research and Treatment Department of Neurology Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USADepartment of Neurology Massachusetts General Hospital Massachusetts General Hospital Harvard Medical School Boston Massachusetts USADepartment of Neurology Massachusetts General Hospital Massachusetts General Hospital Harvard Medical School Boston Massachusetts USACenter for Alzheimer Research and Treatment Department of Neurology Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USADepartment of Neurology Massachusetts General Hospital Massachusetts General Hospital Harvard Medical School Boston Massachusetts USADepartment of Neurology Massachusetts General Hospital Massachusetts General Hospital Harvard Medical School Boston Massachusetts USACenter for Alzheimer Research and Treatment Department of Neurology Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USADepartment of Neurology Massachusetts General Hospital Massachusetts General Hospital Harvard Medical School Boston Massachusetts USADepartment of Neurology Massachusetts General Hospital Massachusetts General Hospital Harvard Medical School Boston Massachusetts USADepartment of Neurology Massachusetts General Hospital Massachusetts General Hospital Harvard Medical School Boston Massachusetts USADepartment of Software Engineering and Artificial Intelligence Complutense University of Madrid Madrid SpainCenter for Alzheimer Research and Treatment Department of Neurology Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USADepartment of Neurology Massachusetts General Hospital Massachusetts General Hospital Harvard Medical School Boston Massachusetts USADepartment of Neurology Massachusetts General Hospital Massachusetts General Hospital Harvard Medical School Boston Massachusetts USADepartment of Neurology Massachusetts General Hospital Massachusetts General Hospital Harvard Medical School Boston Massachusetts USADepartment of Neurology Massachusetts General Hospital Massachusetts General Hospital Harvard Medical School Boston Massachusetts USACenter for Alzheimer Research and Treatment Department of Neurology Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USACenter for Alzheimer Research and Treatment Department of Neurology Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USACenter for Alzheimer Research and Treatment Department of Neurology Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USAAbstract Introduction Unsupervised digital cognitive testing is an appealing means to capture subtle cognitive decline in preclinical Alzheimer's disease (AD). Here, we describe development, feasibility, and validity of the Boston Remote Assessment for Neurocognitive Health (BRANCH) against in‐person cognitive testing and amyloid/tau burden. Methods BRANCH is web‐based, self‐guided, and assesses memory processes vulnerable in AD. Clinically normal participants (n = 234; aged 50–89) completed BRANCH; a subset underwent in‐person cognitive testing and positron emission tomography imaging. Mean accuracy across BRANCH tests (Categories, Face‐Name‐Occupation, Groceries, Signs) was calculated. Results BRANCH was feasible to complete on participants’ own devices (primarily smartphones). Technical difficulties and invalid/unusable data were infrequent. BRANCH psychometric properties were sound, including good retest reliability. BRANCH was correlated with in‐person cognitive testing (r = 0.617, P < .001). Lower BRANCH score was associated with greater amyloid (r = –0.205, P = .007) and entorhinal tau (r = –0.178, P = .026). Discussion BRANCH reliably captures meaningful cognitive information remotely, suggesting promise as a digital cognitive marker sensitive early in the AD trajectory.https://doi.org/10.1002/dad2.12243digital biomarkersmobile testingpreclinical Alzheimer's diseaseunsupervised assessment |
| spellingShingle | Kathryn V. Papp Aubryn Samaroo Hsiang‐Chin Chou Rachel Buckley Olivia R. Schneider Stephanie Hsieh Daniel Soberanes Yakeel Quiroz Michael Properzi Aaron Schultz Iván García‐Magariño Gad A. Marshall Jane G. Burke Raya Kumar Noah Snyder Keith Johnson Dorene M. Rentz Reisa A. Sperling Rebecca E. Amariglio Unsupervised mobile cognitive testing for use in preclinical Alzheimer's disease Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring digital biomarkers mobile testing preclinical Alzheimer's disease unsupervised assessment |
| title | Unsupervised mobile cognitive testing for use in preclinical Alzheimer's disease |
| title_full | Unsupervised mobile cognitive testing for use in preclinical Alzheimer's disease |
| title_fullStr | Unsupervised mobile cognitive testing for use in preclinical Alzheimer's disease |
| title_full_unstemmed | Unsupervised mobile cognitive testing for use in preclinical Alzheimer's disease |
| title_short | Unsupervised mobile cognitive testing for use in preclinical Alzheimer's disease |
| title_sort | unsupervised mobile cognitive testing for use in preclinical alzheimer s disease |
| topic | digital biomarkers mobile testing preclinical Alzheimer's disease unsupervised assessment |
| url | https://doi.org/10.1002/dad2.12243 |
| work_keys_str_mv | AT kathrynvpapp unsupervisedmobilecognitivetestingforuseinpreclinicalalzheimersdisease AT aubrynsamaroo unsupervisedmobilecognitivetestingforuseinpreclinicalalzheimersdisease AT hsiangchinchou unsupervisedmobilecognitivetestingforuseinpreclinicalalzheimersdisease AT rachelbuckley unsupervisedmobilecognitivetestingforuseinpreclinicalalzheimersdisease AT oliviarschneider unsupervisedmobilecognitivetestingforuseinpreclinicalalzheimersdisease AT stephaniehsieh unsupervisedmobilecognitivetestingforuseinpreclinicalalzheimersdisease AT danielsoberanes unsupervisedmobilecognitivetestingforuseinpreclinicalalzheimersdisease AT yakeelquiroz unsupervisedmobilecognitivetestingforuseinpreclinicalalzheimersdisease AT michaelproperzi unsupervisedmobilecognitivetestingforuseinpreclinicalalzheimersdisease AT aaronschultz unsupervisedmobilecognitivetestingforuseinpreclinicalalzheimersdisease AT ivangarciamagarino unsupervisedmobilecognitivetestingforuseinpreclinicalalzheimersdisease AT gadamarshall unsupervisedmobilecognitivetestingforuseinpreclinicalalzheimersdisease AT janegburke unsupervisedmobilecognitivetestingforuseinpreclinicalalzheimersdisease AT rayakumar unsupervisedmobilecognitivetestingforuseinpreclinicalalzheimersdisease AT noahsnyder unsupervisedmobilecognitivetestingforuseinpreclinicalalzheimersdisease AT keithjohnson unsupervisedmobilecognitivetestingforuseinpreclinicalalzheimersdisease AT dorenemrentz unsupervisedmobilecognitivetestingforuseinpreclinicalalzheimersdisease AT reisaasperling unsupervisedmobilecognitivetestingforuseinpreclinicalalzheimersdisease AT rebeccaeamariglio unsupervisedmobilecognitivetestingforuseinpreclinicalalzheimersdisease |